Boston Oncology Arabia is a bio-generic drugs manufacturing company headquartered in Riyadh with a production facility in Sudair Industrial City that develops and manufactures internationally licensed therapeutics. The company provides vital medicines for critical conditions, focusing on specialty generics and biosimilar medications using already approved formulations to meet pharmaceutical quality, safety, and efficacy standards. It aims to increase local production to meet Saudi Arabia’s growing demand and contribute to Vision 2030 by supplying critical care medicines through flexible local manufacturing. TVM Capital Healthcare’s USD 35 million investment will support the company’s move into full formulation and fill-and-finish manufacturing at its Sudair facility and expand access to international suppliers. Management plans to leverage licensing relationships from Western and Eastern markets to bring best-in-class therapeutics to the GCC and MENA region and strengthen its position in oncology and critical care.

Total raised

$35M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2024